Price (delayed)
$3.17
Market cap
$21.12M
P/E Ratio
1.19
Dividend/share
$1.75
EPS
$2.67
Enterprise value
$17.42M
MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in
Special dividends are included in TTM DPS and yield
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.